Viewing nowCombinationOlodipine 5/20 mg Tablets (Amlodipine, Olmesartan Medoxomil)
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.

MFDS item code 201404738 · Approved 2014.10.15 · Insurance code 648103490
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively lower blood pressure in patients with essential hypertension whose blood pressure is not adequately controlled by amlodipine or olmesartan medoxomil monotherapy. It helps reduce the risk of complications, such as heart disease or stroke, through hypertension treatment. It maintains stable blood pressure levels for patients, improving overall cardiovascular health. This treatment allows for additional control when blood pressure regulation is difficult or insufficient with a single agent. It contributes to enhancing the quality of life of patients through systematic blood pressure management. Consequently, it is used to effectively treat essential hypertension.
Take 1 tablet once daily with water, with or without food. It is recommended to take the tablet at the same time each day, if possible (e.g., in the morning). Before starting this drug, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Caution should be exercised when administering this drug to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This drug should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this drug, under Precautions for Use.) ∘Older adults: In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in older adults.
The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, if you are pregnant, you must stop taking it. Those who are allergic to any active or related ingredients in this medication, pregnant or nursing women, patients with severe liver impairment, severe aortic stenosis, biliary obstruction, dialysis patients, patients in shock, and certain diabetic patients should not take this medication. Patients with hypotension due to fluid or salt depletion or those at risk of rapid blood vessel dilation, patients with severe obstructive coronary artery disease, congestive heart failure, reduced renal function, and patients with liver impairment should be particularly cautious when taking this medication. Various side effects such as dizziness, headache, hypotension, edema, dyspepsia, and rash may occur when taking this medication. If any unusual symptoms appear, consult medical personnel immediately. Discontinuing beta-blockers suddenly can be dangerous; therefore, when taking this medication, the reduction of beta-blockers should be done gradually. This medication may interact with other drugs that affect blood pressure control, so if other medications are being taken, it is important to inform your doctor or pharmacist. It is advisable not to use this medication during pregnancy, and if planning to become pregnant or confirming pregnancy, stop taking it immediately and switch to an alternative treatment. Nursing mothers are also recommended to stop breastfeeding or discontinue this medication as it may affect the baby. Children under 18 years of age should not take this medication as safety and efficacy have not been established. Elderly patients should start with a low dose due to possible reduced kidney and liver function and should be monitored carefully while taking this medication. In cases of overdose, severe hypotension or blood vessel dilation may occur, and immediate medical attention should be sought for appropriate treatment. This medication should be kept out of reach of children and stored in a cool, dry place away from direct sunlight and humidity.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to avoid the effects of air and moisture. The recommended storage temperature is room temperature between 1 and 30 degrees Celsius.
White round film-coated tablets
30 tablets (10 tablets/Alu-Alu x 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.